Drug Trial Radar · NCT04628494
A Phase 3 Trial of Epcoritamab vs Investigator's Choice Chemotherapy in Relapsed/Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL)
Last checked: Nov 20, 2026Latest source record: Nov 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
483
Actual
Start
Jan 13, 2021
Primary completion
Oct 13, 2025
Study completion Apr 2028
Sponsor
- Lead sponsor
- GenmabIndustry
- Sponsor type
- Industry
- Collaborators
- AbbVie
- First posted
- Nov 13, 2020
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this trial is to find out if epcoritamab, also known as EPKINLY™ and GEN3013, is safe and works well as treatment for participants with DLBCL that are not responding to treatment, have grown in size, or have come back following treatment with at least 1 prior systemic cancer therapy. All participants in this trial will be randomly assigned to receive either epcoritamab or a pre-specified investigator's choice (standard of care) chemotherapy (either rituximab + gemcitabine + oxaliplatin \[R-GemOx\], or bendamustine + rituximab \[BR\]). Participants must have failed or be ineligible to receive an autologous stem cell transplant (ASCT). Epcoritamab will be injected under the skin. Investigator's choice chemotherapy will be given intravenously. Trial details include: * The trial duration will be up to 5 years after last participant is randomized. * All trial participants have a 21-day screening period, a treatment period, and a follow-up period that continues until death. * The estimated trial duration for an individual participant depends upon the treatment arm assigned: * Participants who receive epcoritamab will have 28-day treatment cycles. Epcoritamab will be given once weekly for the first 3 months, then every other week for 6 months, then every 28 days until lymphoma progression or unacceptable adverse events. * Participants who receive investigator's choice (standard of care) chemotherapy will receive treatments either: * R-GemOx: On Day 1 (or Day 1 \& Day 2), and Day 15 (or Day 15 \& Day 16) every 28 days, for up to 4 months; or * BR: On Day 1 and Day 2 every 3 weeks for up to 4.5 months.
Conditions
- Diffuse Large B-cell Lymphoma
Interventions
EpcoritamabBiological
Following mandatory pre-medication, participants will be administered epcoritamab as a subcutaneous injection.
Investigator's Choice ChemotherapyDrug
Following mandatory pre-medication, participants will be administered intravenously either BR or R-GemOx.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Overall Survival (OS)Time frame: Up to approximately 4 years, 9 months
Locations
186 sites in 24 countries. Site status is shown where the registry gives one.
Indiana Blood and Marrow Transplantation
Indianapolis, Indiana
Community Health Network Cancer Center North
Indianapolis, Indiana
University of Kentucky Markey Cancer Center
Lexington, Kentucky
Henry Ford Health System
Jackson, Michigan
MMCORC Attn Delaney Anderson
Saint Louis Park, Minnesota
MD Anderson Cancer Center at Cooper
Camden, New Jersey
Wake Forest Baptist Health
Winston-Salem, North Carolina
The Christ Hospital Cancer Center
Cincinnati, Ohio
TriHealth Cancer Institute- Good Samaritan Hospital
Cincinnati, Ohio
Brooke Army Medical Center
Fort Sam Houston, Texas
Community Cancer Trials of Utah
Ogden, Utah
LDS Hospital
Salt Lake City, Utah
Virginia Commonwealth University (VCU) Massey Cancer Center
Richmond, Virginia
North Star Lodge Cancer Center
Yakima, Washington
Waukesha Memorial Hospital
Waukesha, Wisconsin
Flinders Medical Centre
Bedford Park, Australia
Concord Repatriation General Hospital
Concord, Australia
Peninsula Private Hospital Clinical Trials Unit
Frankston, Australia
Icon Cancer Centre Corporate Office
South Brisbane, Australia
Calvary Mater Newcastle
Waratah, Australia
Westmead Hospital
Westmead, Australia
Ordensklinikum Linz Barmherzige Schwestern
Linz, Austria
Ordensklinikum Linz GmbH Elisabethinen
Linz, Austria
Uniklinikum Salzburg, Universitätsklinik für Innere Medizin III der PMU
Salzburg, Austria
ZNA Middelheim
Antwerp, Belgium
AZ Sint-Jan
Bruges, Belgium
Institut Jules Bordet
Brussels, Belgium
Universitair Ziekenhuis Gent
Ghent, Belgium
UZ Brussel
Jette, Belgium
Hôpital de Jolimont
La Louvière, Belgium
Universitair Ziekenhuis gasthuisberg Leuven
Leuven, Belgium
AZ Nikolaas- Verenigde Ziekenhuizen van Waas en Durme
Sint-Niklaas, Belgium
AZ Turnhout, Campus Sint-Elisabeth
Turnhout, Belgium
CHU de Quebec-Universite Laval
Québec, Canada
Aalborg Universitetshospital
Aalborg, Denmark
Aarhus University Hospital, Department of Hematology, Clinical Research Unit C116
Aarhus, Denmark
Clinical Research Unit, Roskilde Sygehus
Roskilde, Denmark
Vejle Hospital
Vejle, Denmark
HUS Cancer Center/ Clinical Trial Unit
Helsinki, Finland
Oulu university hospital, Department of hematology
Oulu, Finland
Showing 40 of 186 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.